文献速递心脑血管急症消化、代谢与肾脏急症重症综合管理与镇静镇痛

鱼油补充与血液透析患者心血管事件

Fish-Oil Supplementation and Cardiovascular Events in Patients Receiving Hemodialysis.
PubMed 文献 · N Engl J Med · 2025-11-07
一句话结论维持性血液透析患者每日补充4 g n-3多不饱和脂肪酸(1.6 g EPA和0.8 g DHA)可显著降低严重心血管事件发生率(HR 0.57,95%CI 0.47–0.70)。

该双盲、随机、安慰剂对照试验在加拿大和澳大利亚26个中心纳入1228例维持性血液透析成人患者,随机分为每日鱼油补充组(4 g n-3多不饱和脂肪酸,含1.6 g EPA和0.8 g DHA)或玉米油安慰剂组。中位随访3.5年期间,鱼油组严重心血管事件发生率为0.31/1000患者日,安慰剂组为0.61/1000患者日(HR 0.57,95%CI 0.47–0.70,P<0.001)。扩展主要终点(含非心脏原因死亡)HR为0.77(95%CI 0.65–0.90),心脏死亡HR 0.55(95%CI 0.40–0.75),致死性和非致死性心肌梗死HR 0.56(95%CI 0.40–0.80),导致截肢的外周血管病HR 0.57(95%CI 0.38–0.86),致死性和非致死性卒中HR 0.37(95%CI 0.18–0.76),首次心血管事件或全因死亡HR 0.73(95%CI 0.61–0.87)。两组依从性和不良事件发生率无有意义的差异。

要点

  • 维持性血液透析患者每日补充4 g n-3多不饱和脂肪酸(1.6 g EPA和0.8 g DHA)显著降低严重心血管事件复合终点(0.31 vs 0.61/1000患者日;HR 0.57,95%CI 0.47–0.70,P<0.001)。
  • 鱼油组心脏死亡风险显著低于安慰剂组(HR 0.55,95%CI 0.40–0.75),致死性和非致死性心肌梗死风险显著降低(HR 0.56,95%CI 0.40–0.80)。
  • 鱼油组致死性和非致死性卒中风险显著低于安慰剂组(HR 0.37,95%CI 0.18–0.76),导致截肢的外周血管病风险显著降低(HR 0.57,95%CI 0.38–0.86)。
  • 扩展主要终点(含非心脏原因死亡)在鱼油组似乎更低(HR 0.77,95%CI 0.65–0.90),首次心血管事件或全因死亡HR 0.73(95%CI 0.61–0.87)。
  • 两组依从性和不良事件发生率无有意义的差异。

适用人群与场景

  • 接受维持性血液透析的成人患者,来自加拿大和澳大利亚26个中心。

处置流程与药物剂量

  • 鱼油组每日补充4 g n-3多不饱和脂肪酸(含1.6 g EPA和0.8 g DHA);安慰剂组每日补充玉米油。

研究设计与关键结果

  • 双盲、随机、安慰剂对照试验,在加拿大和澳大利亚26个中心纳入1228例维持性血液透析成人患者,随机分为鱼油组(610例)和安慰剂组(618例)。
  • 中位随访3.5年,鱼油组严重心血管事件发生率为0.31/1000患者日,安慰剂组为0.61/1000患者日(HR 0.57,95%CI 0.47–0.70,P<0.001)。
  • 扩展主要终点(含非心脏原因死亡)HR为0.77(95%CI 0.65–0.90)。
  • 心脏死亡HR 0.55(95%CI 0.40–0.75);致死性和非致死性心肌梗死HR 0.56(95%CI 0.40–0.80);导致截肢的外周血管病HR 0.57(95%CI 0.38–0.86);致死性和非致死性卒中HR 0.37(95%CI 0.18–0.76);首次心血管事件或全因死亡HR 0.73(95%CI 0.61–0.87)。
  • 两组依从性和不良事件发生率无有意义的差异。

证据类型、等级与局限

  • 证据类型:双盲、随机、安慰剂对照试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在维持性血液透析患者中,每日补充n-3多不饱和脂肪酸(4 g,含1.6 g EPA和0.8 g DHA)较安慰剂可降低严重心血管事件发生率。

指南或共识出处

  • PISCES试验(ClinicalTrials.gov编号ISRCTN00691795),由加拿大心脏与卒中基金会等资助。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Cardiovascular disease is the leading cause of death in patients receiving hemodialysis, yet effective preventive therapies remain limited. Supplementation with n-3 polyunsaturated fatty acids, especially eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), may have cardiovascular benefits in the general population, but efficacy among patients receiving hemodialysis is uncertain.

METHODS: In a double-blind, randomized, placebo-controlled trial conducted at 26 sites in Canada and Australia, we assigned adult patients receiving maintenance hemodialysis to daily supplementation with fish oil (4 g of n-3 polyunsaturated fatty acids [1.6 g of EPA and 0.8 g of DHA]) or corn-oil placebo. The primary end point was a composite of all serious cardiovascular events including sudden and nonsudden cardiac death, fatal and nonfatal myocardial infarction, peripheral vascular disease leading to amputation, and fatal and nonfatal stroke. Secondary end points included extension of the primary end point to include noncardiac causes of death, the individual components of the primary end point, and a first cardiovascular event or death from any cause.

RESULTS: Between November 28, 2013, and July 22, 2019, a total of 1228 participants underwent randomization; 610 were assigned to the fish-oil group and 618 to the placebo group. During 3.5 years of follow-up, the rate of serious cardiovascular events was significantly lower in the fish-oil group than in the placebo group (0.31 vs. 0.61 per 1000 patient-days; hazard ratio, 0.57; 95% confidence interval [CI], 0.47 to 0.70; P<0.001). The rate of the extended primary end point that included noncardiac causes of death appeared to be lower in the fish-oil group than in the placebo group, with a hazard ratio of 0.77 (95% CI, 0.65 to 0.90). The hazard ratio for cardiac death was 0.55 (95% CI, 0.40 to 0.75); for fatal and nonfatal myocardial infarction, 0.56 (95% CI, 0.40 to 0.80); for peripheral vascular disease leading to amputation, 0.57 (95% CI, 0.38 to 0.86); for fatal and nonfatal stroke, 0.37 (95% CI, 0.18 to 0.76); and for a first cardiovascular event or death from any cause, 0.73 (95% CI, 0.61 to 0.87). Adherence to the trial regimen and the incidence of adverse events did not differ meaningfully between the groups.

CONCLUSIONS: The rate of serious cardiovascular events among participants receiving maintenance hemodialysis was lower with daily supplementation with n-3 fatty acids than with placebo. (Supported by the Heart and Stroke Foundation of Canada and others; PISCES ClinicalTrials.gov number, ISRCTN00691795.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Lok CE, Farkouh M, Hemmelgarn BR, et al. Fish-Oil Supplementation and Cardiovascular Events in Patients Receiving Hemodialysis. N Engl J Med. 2025. PMID: 41201837. doi:10.1056/NEJMoa2513032

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。